JP6758279B2 - ケモカインを含む皮膚美白用組成物 - Google Patents
ケモカインを含む皮膚美白用組成物 Download PDFInfo
- Publication number
- JP6758279B2 JP6758279B2 JP2017504075A JP2017504075A JP6758279B2 JP 6758279 B2 JP6758279 B2 JP 6758279B2 JP 2017504075 A JP2017504075 A JP 2017504075A JP 2017504075 A JP2017504075 A JP 2017504075A JP 6758279 B2 JP6758279 B2 JP 6758279B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- melanin
- factor
- cell
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 34
- 230000002087 whitening effect Effects 0.000 title description 9
- 102000019034 Chemokines Human genes 0.000 title description 8
- 108010012236 Chemokines Proteins 0.000 title description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 35
- 239000000049 pigment Substances 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 102000003425 Tyrosinase Human genes 0.000 claims description 11
- 108060008724 Tyrosinase Proteins 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 102000014150 Interferons Human genes 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 229940079322 interferon Drugs 0.000 claims description 8
- 230000035605 chemotaxis Effects 0.000 claims description 7
- 102000003964 Histone deacetylase Human genes 0.000 claims description 6
- 108090000353 Histone deacetylase Proteins 0.000 claims description 6
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 5
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 5
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 5
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims description 5
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 5
- 101800001271 Surface protein Proteins 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 4
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims description 4
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 29
- 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 description 27
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 14
- 210000002752 melanocyte Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- 238000001190 Q-PCR Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003101 melanogenic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000037204 skin physiology Effects 0.000 description 2
- -1 skins Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101150077068 Hdac5 gene Proteins 0.000 description 1
- 108050004676 Histone deacetylase 5 Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Cascade社から購入したヒトメラニン形成細胞(Normal Human Epidermal Melanocyte−Moderately pigmented、製品番号C−102−5C)を、100cm2のプレートに6×105個を植え、基本培地はHMGS(Human Melanocyte Growth Supplement;製品番号S−002−5、Gibco)を含む254培地(製品番号M−254−500、Gibco)を用い、37℃で、5%のCO2インキュベーターで培養した。約70〜80%の密度になったとき継代培養をし、その後に行われる実験に、継代培養したメラニン形成細胞を提供した。
ITACによってメラニン形成細胞の色素生成が減少されるか否かを確認するために、ヒトメラニン形成細胞にITACを処理した。ITACはR&Dシステムで製造した製品番号672−ITを利用した。
上記参考例1で培養されたヒトメラニン形成細胞に、50ng/mlのITAC(製品番号672−IT、R&Dシステム)を48時間処理した。これから分離したRNAからcDNAを合成し、HDAC5(Histone deacetylase5;ヒストン脱アセチル化酵素)のプライマーを利用して、Q−PCR(アプライドバイオシステムズ、7500Fast)でmRNA量の変化を測定した。Q−PCRの実験については、95℃で15秒、60℃で60秒間のサイクルを合計40回繰り返し、対照群の遺伝子発現に比べて該遺伝子の発現がどれぐらい増加したのか、相対的値を測定した。上記実験に利用したHDAC5プライマーは、アプライドバイオシステムズで製造したTaqMan製品で、製品番号:Hs00608366_m1を利用した。
HDAC5過剰発現ベクター(HDAC5 overexpression vector)を利用して、HDAC5のタンパク質を対照群細胞より過剰に作り出すメラニン形成細胞を、遠心分離〔エッペンドルフ(eppendorf)、centrifuge 5415R、Germany〕し、そのペレットを分離して色を観察した。
Claims (10)
- インターフェロン誘導性T細胞α走化性因子を有効成分として含有することを特徴とする、メラニン形成細胞のメラニン色素生成関連因子の遺伝子発現抑制用の組成物〔ここで、メラニン形成細胞のメラニン色素生成関連因子は、チロシナーゼ(TYR)、MITF、TYRP1、DCT、MART1及びgp100から選ばれる少なくとも一つである〕。
- インターフェロン誘導性T細胞α走化性因子を有効成分として含有することを特徴とする、ヒストン脱アセチル化酵素の遺伝子発現増加用の組成物。
- インターフェロン誘導性T細胞α走化性因子を有効成分として含有することを特徴とする、過色素性皮膚疾患の改善用の組成物。
- 前記インターフェロン誘導性T細胞α走化性因子は、組成物の総重量に対して、0.0001〜0.0005重量%の量で含有されることを特徴とする請求項1〜3の何れか一項に記載の組成物。
- 前記インターフェロン誘導性T細胞α走化性因子の濃度が、50〜200ng/mlであることを特徴とする請求項1〜3の何れか一項に記載の組成物。
- 前記過色素性皮膚疾患は、シミまたはほくろであることを特徴とする請求項3に記載の組成物。
- 前記過色素性皮膚疾患は、炎症後の色素沈着によるものであることを特徴とする請求項3に記載の組成物。
- 前記組成物は、皮膚外用剤組成物であることを特徴とする請求項1〜7の何れか一項に記載の組成物。
- 前記組成物は、化粧料組成物であることを特徴とする請求項1〜7の何れか一項に記載の組成物。
- インターフェロン誘導性T細胞α走化性因子を有効成分として含有する組成物の、メラニン形成細胞のメラニン色素生成関連因子の遺伝子発現を抑制するための使用方法(但し、ヒトに対する医療行為を除く)〔ここで、メラニン形成細胞のメラニン色素生成関連因子は、チロシナーゼ(TYR)、MITF、TYRP1、DCT、MART1及びgp100から選ばれる少なくとも一つである〕。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140098395A KR102152637B1 (ko) | 2014-07-31 | 2014-07-31 | 케모카인을 함유하는 피부 미백용 조성물 |
KR10-2014-0098395 | 2014-07-31 | ||
PCT/KR2015/007721 WO2016018001A1 (ko) | 2014-07-31 | 2015-07-24 | 케모카인을 함유하는 피부 미백용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017523177A JP2017523177A (ja) | 2017-08-17 |
JP6758279B2 true JP6758279B2 (ja) | 2020-09-23 |
Family
ID=55217816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017504075A Expired - Fee Related JP6758279B2 (ja) | 2014-07-31 | 2015-07-24 | ケモカインを含む皮膚美白用組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10045926B2 (ja) |
EP (1) | EP3162358B1 (ja) |
JP (1) | JP6758279B2 (ja) |
KR (1) | KR102152637B1 (ja) |
CN (1) | CN106572956B (ja) |
TW (1) | TWI680770B (ja) |
WO (1) | WO2016018001A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018012889A1 (ko) * | 2016-07-13 | 2018-01-18 | (주)아모레퍼시픽 | Itac의 억제제를 포함하는 조성물 |
KR20180007669A (ko) * | 2016-07-13 | 2018-01-23 | (주)아모레퍼시픽 | Itac의 억제제를 포함하는 조성물 |
KR101698447B1 (ko) | 2016-08-10 | 2017-01-20 | 테고사이언스 (주) | 케모카인을 유효성분으로 포함하는 피부개선용 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1399184A2 (en) * | 2000-12-01 | 2004-03-24 | Schering Corporation | Uses of mammalian genes and related reagents |
WO2002059301A1 (en) | 2001-01-27 | 2002-08-01 | K.U. Leuven Research And Development | Chemokines |
AU2003259117A1 (en) | 2002-07-10 | 2004-01-23 | The Regents Of The University Of California | Antimicrobial activity of interferon-inducible elr chemokines |
US20070092488A1 (en) | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
JP5300223B2 (ja) * | 2007-07-31 | 2013-09-25 | 株式会社マンダム | 発現抑制剤及び被験物質の評価方法 |
KR101871922B1 (ko) | 2011-11-23 | 2018-07-02 | (주)아모레퍼시픽 | 케모카인을 함유하는 성체 멜라닌 세포 이동 촉진용 조성물, 케모카인 유전자를 이용하여 피부 활성물질 탐색용 키트 및 이를 이용하여 피부 활성물질을 탐색하는 방법 |
-
2014
- 2014-07-31 KR KR1020140098395A patent/KR102152637B1/ko active IP Right Grant
-
2015
- 2015-07-24 EP EP15827547.9A patent/EP3162358B1/en active Active
- 2015-07-24 JP JP2017504075A patent/JP6758279B2/ja not_active Expired - Fee Related
- 2015-07-24 WO PCT/KR2015/007721 patent/WO2016018001A1/ko active Application Filing
- 2015-07-24 US US15/329,316 patent/US10045926B2/en active Active
- 2015-07-24 CN CN201580040962.2A patent/CN106572956B/zh active Active
- 2015-07-29 TW TW104124487A patent/TWI680770B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2016018001A1 (ko) | 2016-02-04 |
CN106572956A (zh) | 2017-04-19 |
EP3162358A1 (en) | 2017-05-03 |
CN106572956B (zh) | 2020-07-03 |
JP2017523177A (ja) | 2017-08-17 |
TWI680770B (zh) | 2020-01-01 |
KR102152637B1 (ko) | 2020-09-08 |
EP3162358A4 (en) | 2018-02-21 |
US20170209358A1 (en) | 2017-07-27 |
KR20160015745A (ko) | 2016-02-15 |
TW201603826A (zh) | 2016-02-01 |
EP3162358B1 (en) | 2020-06-03 |
US10045926B2 (en) | 2018-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101831887B1 (ko) | 발모 촉진 활성 및 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
KR101525298B1 (ko) | 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도 | |
KR101755091B1 (ko) | 플로레틴의 항여드름 및 항염증 용도 | |
TWI769167B (zh) | 皮膚外用的抗氧化組成物 | |
JP6758279B2 (ja) | ケモカインを含む皮膚美白用組成物 | |
KR101800877B1 (ko) | 발모 촉진 활성 및 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
CN112236441A (zh) | 大气污染物质导致的皮肤损伤防止及抗老化用肽及其用途 | |
WO2015174599A1 (ko) | 저색소증 개선 및 지방 형성 억제 효능을 갖는 펩타이드 및 이의 용도 | |
KR20130103945A (ko) | 플라본 화합물의 15-하이드록시프로스타글란딘 탈수소효소 활성의 억제 효능 및 그의 용도 | |
KR100968367B1 (ko) | 카페인산 유도체 및 이를 유효성분으로 포함하는 조성물 | |
JP5196465B2 (ja) | Mmp遺伝子発現促進剤、および、コラーゲン分解促進剤 | |
KR101945349B1 (ko) | 물질 p를 포함하는 주름 개선 또는 항염증 화장료 조성물 | |
KR20150108088A (ko) | 능실 추출물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물 | |
CN109640974A (zh) | 多咖啡酰基奎尼酸的酰胺衍生物、其制备方法和用途 | |
KR101893339B1 (ko) | Gdf11을 포함하는 조성물 및 그의 용도 | |
KR101375783B1 (ko) | 백반증 예방 또는 치료용 조성물 | |
KR20180055103A (ko) | 유칼립투스 추출물을 포함하는 여드름 피부 개선용 화장료 조성물 | |
KR20210066532A (ko) | 페룰산 및 이의 유사체를 포함하는 유전자 돌연변이에 의한 피부질환 예방 및 치료용 조성물 | |
KR102010950B1 (ko) | 인터루킨 16을 포함하는 피부 외용제 조성물 | |
WO2021215440A1 (ja) | ヒアルロン酸産生促進剤 | |
KR102027451B1 (ko) | 마이크로 rna 및 이를 사용하는 스크리닝 방법 | |
JP6901801B2 (ja) | 物質pを含むしわの改善または抗炎症化粧料組成物 | |
CN110547975B (zh) | 包含表松脂酚的化妆材料组合物 | |
KR102010951B1 (ko) | 인터루킨 27을 포함하는 피부 외용제 조성물 | |
KR101221593B1 (ko) | H19 microRNA을 함유하는 기미 발생 억제용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180517 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190411 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190722 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200804 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200901 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6758279 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |